Valuation: Perspective Therapeutics, Inc.

Market Cap 332M 291M 271M 249M 467M 31.96B 475M 3.22B 1.26B 15.71B 1.25B 1.22B 54.33B P/E 2026 *
-2.64x
P/E 2027 * -2.57x
Enterprise Value 145M 127M 118M 108M 204M 13.94B 207M 1.4B 549M 6.85B 543M 532M 23.7B EV / Sales 2026 *
342x
EV / Sales 2027 * 40.1x
Free-Float
89.19%
Yield 2026 *
-
Yield 2027 * -
1 day-1.36%
1 week-2.68%
Current month-14.66%
1 month-3.00%
3 months-35.48%
6 months+7.38%
Current year+5.82%
1 week 2.85
Extreme 2.85
3.03
1 month 2.82
Extreme 2.82
3.78
Current year 2.25
Extreme 2.25
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 2023-02-04
Director of Finance/CFO 59 2025-09-03
Chief Tech/Sci/R&D Officer - 2026-07-07
Director TitleAgeSince
Director/Board Member 54 2023-02-04
Chairman 63 2023-02-02
Director/Board Member 60 2023-02-04
Date Insider Type Main position Quantity % Market Cap.
3/2/26 Free

Director

50,000 0.0439%
3/2/26 Free

Chairman

50,000 0.0439%
3/2/26 Free

Chief Technology Officer

150,000 0.1317%
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%-2.68%-29.88%-53.20% 336M
+1.07%-3.49%-3.25%+12.87% 46.35B
+0.25%+1.65%+408.41%+629.49% 40.13B
-0.27%+4.45%+9.93%+66.92% 36.33B
+0.35%+0.87%+3.60%-8.81% 34.6B
+3.14%+1.02%+3.37%+38.15% 26.77B
-0.73%+11.84%+31.97%+143.53% 16.91B
+0.47%-2.74% - - 16.66B
+0.42%-5.52%+0.76%+8.50% 13.05B
-2.68%-2.49%-15.00%-31.68% 13.05B
Average +0.07%+0.89%+45.55%+89.53% 24.42B
Weighted average by Cap. +0.46%+1.10%+75.41%+136.74%

Financials

2026 *2027 *
Net sales 423K 372K 346K 317K 596K 40.75M 605K 4.1M 1.6M 20.03M 1.59M 1.55M 69.27M 488K 428K 398K 365K 687K 46.95M 697K 4.73M 1.85M 23.08M 1.83M 1.79M 79.81M
Net income -120M -106M -98.12M -90.03M -169M -11.57B -172M -1.17B -455M -5.69B -451M -441M -19.66B -138M -121M -113M -104M -195M -13.3B -198M -1.34B -524M -6.54B -519M -507M -22.61B
Net Debt -187M -164M -153M -140M -264M -18.02B -268M -1.81B -709M -8.86B -702M -687M -30.63B -312M -274M -255M -234M -440M -30.08B -447M -3.03B -1.18B -14.79B -1.17B -1.15B -51.12B
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
26-07-24 $2.910 -1.36% 671,173
26-07-23 $2.950 -0.67% 582,707
26-07-22 $2.970 -0.34% 1,151,847
26-07-21 $2.980 +2.05% 873,942
26-07-20 $2.920 -2.34% 915,956
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.910USD
Average target price
12.93USD
Spread / Average Target
+344.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CATX Stock